Oscar Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Oscar Health (OSCR) has gained attention due to a Zacks Rank #1, rising earnings estimates, and a PEG ratio below industry average. Its share price has surged 108.68% year-to-date, with strong momentum. A popular narrative values the stock at $583.34, citing aggressive growth assumptions, but cautions about potential revenue slowdowns or margin pressures.
UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.
Oscar Health (OSCR) hit a 52-week high of $33.54, with a 90.7% total return over the past year. The company reported Q2 2026 adjusted earnings of $1.10 per share, beating estimates of $0.37, and revenue of $4.88 billion, exceeding expectations. InvestingPro suggests the stock may be overvalued, with a high beta of 2.39.
Over the past 7 days, alphai's AI scored 3 news stories mentioning OSCR (Oscar Health, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent OSCR coverage spans earnings, financial news and insider activity.
In the last 30 days, OSCR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($595K). The most active reporter was Blackley Richard Scott, Chief Financial Officer, with 1 filing.
Potential short-term price lift from upgraded rating.
Rapid share price rise reflects market optimism on expansion.
Strong earnings surprise may drive short-term upside.
Strong earnings beat and positive guidance likely support further upside.
Minor dilution of insider holdings; unlikely to move price materially.
alphai scores every news story that mentions OSCR with an AI model for sentiment and relevance, and aggregates insider trades from Oscar Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oscar Health (OSCR) has gained attention due to a Zacks Rank #1, rising earnings estimates, and a PEG ratio below industry average. Its share price has surged 108.68% year-to-date, with strong momentum. A popular narrative values the stock at $583.34, citing aggressive growth assumptions, but cautions about potential revenue slowdowns or margin pressures.
2 min readUnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.
3 min readOscar Health (OSCR) hit a 52-week high of $33.54, with a 90.7% total return over the past year. The company reported Q2 2026 adjusted earnings of $1.10 per share, beating estimates of $0.37, and revenue of $4.88 billion, exceeding expectations. InvestingPro suggests the stock may be overvalued, with a high beta of 2.39.
2 min readOscar Health (OSCR) shares rose 12% to a 5-year high after the company reported strong Q1 earnings and optimistic guidance for 2026. CFO Scott Blackley cited favorable industry trends and potential upside to guidance, with membership growing 56% year-over-year to 3.17 million. The company's medical loss ratio improved to 70.5% from 75.4%. OSCR stock has gained 78% over the past year.
2 min readBlackley Richard Scott (Chief Financial Officer) sold 18,750 indirectly-held shares of Oscar Health, Inc. (OSCR) at $31.74 ($0.60M total) on 2026-08-18.
1 min readOscar Health (OSCR) reported a shift to profitability in Q2 and the first half of 2026, with net income of $361.81 million in Q2 and $1.04 billion for H1. On Aug. 6, 2026, it raised 2026 guidance to $18.7–$19.0 billion revenue and $500–$700 million operating earnings. The article notes analysts may need to reassess 2029 outlooks.
4 min readApple shares (AAPL) hit a 52-week high after the company unveiled “Siri AI” at its WWDC, with the assistant using Google Gemini tech. Oscar Health (OSCR) rose to a 52-week high after reaffirming 2026 revenue guidance of $18.7B to $19B. Eli Lilly (LLY) reached a record high on positive late-stage results for oral obesity drug Foundayo and plans to seek U.S. approval for Type 2 diabetes.
4 min readSimply Wall St reports Oscar Health (OSCR) released Q2 2026 results that swung to net income of $361.81 million and raised full-year earnings guidance. The stock fell 11.9% after the update. The article cites OSCR’s valuation at $32.76 versus a “fair value” of $583.34 and highlights ROIC, cash conversion, and net cash.
5 min readOscar Health (OSCR) shares fell 11.9% to $26.54 on Aug. 6 after results and raised guidance. OSCR reported Q2 revenue up 70% to $4.88B and net income of $361.8M. Medical loss ratio fell to 79.2% and operating income rose to $388.6M. Full-year operating-income guidance increased to $500M-$700M, but investors focused on expected second-half seasonality, risk adjustment, and churn.
6 min readA Q2 earnings roundup covers health insurers and related providers. CVS Health (CVS) reported $106.1B revenue (+7.3% YoY), beating EPS and full-year EPS guidance; shares fell 8.4% to $95.66. Progyny (PGNY) revenue was $350.5M (+5.3%), but guidance missed; stock down 7.8% to $27.87. Humana (HUM) revenue $40.87B (+26.2%) and Clover Health (CLOV) revenue $743.2M (+55.6%) both beat; CLOV rose 9.9% to $4.55.
7 min read
